Koos Burggraaf
Hoogleraar
- Naam
- Prof. dr. J. Burggraaf
- Telefoon
- 071 5276211
- j.burggraaf@lacdr.leidenuniv.nl
Koos Burggraaf is hoogleraar Translational Drugs Research bij de divisie Pharmacology bij het Leiden Academic Centre for Drug Research en directeur van het Centre for Human Drug Research (CHDR), gevestigd op het Leiden Bio Science Park.
Oud-promovendi
Hoogleraar
- Faculteit der Wiskunde en Natuurwetenschappen
- LACDR
- LACDR Research
Hoogleraar
- Faculteit Geneeskunde
- LUMC
- Voorde W. ten, Wind S., Abdisalaam I., Mancini A., Linders F., Jansen M.A.A., Niemeyer-van der Kolk T., Burggraaf J. & Rissmann R. (2025), A suction blister model to characterize epidermal wound healing and evaluate the efficacy of the topical wound healing agent INM-755 in healthy volunteers, European Journal of Pharmaceutical Sciences 204: 106867.
- Houvast R.D., Badr N., March T., Muynck L.D.A.N. de, Sier V.Q., Schomann T., Bhairosingh S., Baart V.M., Peeters J.A.H.M., Westen G.J.P. van, Plückthun A., Burggraaf J., Kuppen P.J.K., Vahrmeijer A.L. & Sier C.F.M. (2024), Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer, European Journal of Nuclear Medicine and Molecular Imaging 51: 2179-2192.
- Achterberg F.B., Bijlstra O.D., Slooter M.D., Sibinga Mulder B.G., Boonstra M.C., Bouwense S.A., Bosscha K., Coolsen M.M.E., Derksen W.J.M., Gerhards M.F., Gobardhan P.D., Hagendoorn J., Lips D., Marsman H.A., Zonderhuis B.M., Wullaert L., Putter H., Burggraaf J., Mieog J.S.D., Vahrmeijer A.L. & Swijnenburg R.J. (2024), ICG-Fluorescence Imaging for Margin Assessment During Minimally Invasive Colorectal Liver Metastasis Resection, Jama Network Open 7(4): e246548.
- Veld A.E. in 't, Eveleens Maarse B.C., Juachon M.J., Meziyerh S., Vries A.P.J. de, Rijn A.L. van, Feltkamp M.C.W., Moes D.J.A.R., Burggraaf J. & Moerland M. (2024), Immune responsiveness in stable kidney transplantation patients: complete inhibition of T‐cell proliferation but residual T‐cell activity during maintenance immunosuppressive treatment, Clinical and Translational Science 17(6): e13860.
- Plas J.L. van der, Haijema B.J., Leenhouts K., Zoetweij J.P., Burggraaf J. & Kamerling I.M.C. (2024), Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): a randomized, double-blind, controlled, ascending dose study in healthy adults and elderly, Vaccine 42(22): 125836.
- Linders D.G.J., Bijlstra O.D., Walker E., March T.L., Pool M., Valentijn A.R.P.M., Dijkhuis T.H., Woltering J.N., Pijl F.R., Noordam G., Burg D. van den, Sijp J.R.M. van der, Guicherit O.R., Marinelli A.W.K.S., Burggraaf J., Rissmann R., Bogyo M., Hilling D.E., Kuppen P.J.K., Straight B., Straver M.E., Hazelbag H.M., Basilion J.P. & Vahrmeijer A.L. (2024), Ex vivo fluorescence-guided resection margin assessment in breast cancer surgery using a topically applied, cathepsin-activatable imaging agent, Pharmacological Research 209: 107464.
- Voorde W. ten: Saghari M., Boltjes J., Kam M.L. de, Zhuparris A., Feiss G., Buters T.P., Prens E.P., Damman J., Niemeyer-van der Kolk T., Moerland M., Burggraaf J., Doorn M.B.A. van & Rissmann R. (2023), A multimodal, comprehensive characterization of a cutaneous wound model in healthy volunteers, Experimental Dermatology 32(7): 1028-1041.
- Rousel J., Nadaban A., Saghari M., Pagan L., Zhuparris A., Theelen B., Gambrah T., Wall H.E.C. van der, Vreeken R.J., Feiss G.L., Niemeyer-van der Kolk T., Burggraaf J. Doorn M.B.A. van, Bouwstra J.A. & Rissmann R. (2023), Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition, Experimental Dermatology 33(1): 14952.
- Rousel J., Saghari M., Pagan L., Nadaban A., Gambrah T., Theelen B., Kam M.L. de, Haakman J., Wall H.E.C. van der, Feiss G.L., Niemeyer-van der Kolk T., Burggraaf J., Bouwstra J.A., Rissmann R. & Doorn M.B.A. van (2023), Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial, International Journal of Molecular Sciences 24(18): 14315.
- Pagan L., Huisman B.W., Wurff M. van der, Naafs R.G.C., Schuren F.H.J., Sanders I.M.J.G., Smits W.K., Zwittink R.D., Burggraaf J., Rissmann R., Piek J.M.J., Henderickx J.G.E. & Poelgeest M.I.E. van (2023), The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions, Frontiers in Microbiology 14: 1264768.
- Veld A.E. in 't, Jansen M.A.A., Kam M.L. de, Yavuz Y., Moes D.J.A.R., Oudhoff K. A., Poelgeest M.I.E. van, Burggraaf J. & Moerland M. (2023), Immune monitoring of mycophenolate mofetil activity in healthy volunteers using ex vivo T cell function assays, Pharmaceutics 15(6): 1635.
- Huisman B.W., Nené L.E.H., Linders F.L.L., Gambrah T.K., Kolk T.N. van der, Kam M.L. de, Bavinck J.N.B., Burggraaf J., Feiss G. & Rissmann R. (2023), No effect of topical digoxin and furosemide for patients with actinic keratosis, Journal of the European Academy of Dermatology and Venereology 37(2): e172-e174.
- Linders D.G.J., Bijlstra O.D., Fallert L.C., Hilling D.E., Walker E., Straight B., March T.L., Valentijd A.R.P.M., Pool M., Burggraaf J., Basilion J.P., Vahrmeijer A.L. & Kuppen P.J.K. (2023), Cysteine cathepsins in breast cancer: promising targets for fluorescence-guided surgery, Molecular Imaging and Biology 25: 58-73.
- Buters T.P., Hameeteman P., Jansen I..H.M., Hindevoort F.C. van, Voorde W. ten., Grievink H.W., Schoonakker M., Kam M.L. de, Gilroy D.W., Feiss G., Rissmann R., Jansen M.A.A., Burggraaf J. & Moerland M. (2022), Clinical, cellular, and molecular effects of Corticosteroids on the response to Intradermal Lipopolysaccharide administration in healthy volunteers, Clinical Pharmacology & Therapeutics 111(4): 964-971.
- Saghari M., Gal P., Gilbert S., Yateman M., Porter-Brown B., Brennan N., Quaratino S., Wilson R., Grievink H.W., Klaassen E.S., Bergmann K.R., Burggraaf J., Doorn M.B.A. van, Powell J., Moerland M. & Rissmann R. (2022), OX40L Inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005, Clinical Pharmacology & Therapeutics 111(5): 1121-1132.
- Wall H.E.C. van der, Hassing G.J., Doll R.J., Westen G.J.P. van, Cohen A.F., Selder J.L., Kemme M., Burggraaf J. & Gal P. (2022), Cardiac age detected by machine learning applied to the surface ECG of healthy subjects: creation of a benchmark, Journal of Electrocardiology 72: 49-55.
- Wind S.S., Jansen M.A.A., Rijsbergen M., Esdonk M.J. van, Ziagkos D., Cheng W.C., Kolk-Niemeyer T. van der, Korsten J., Gruszka A., Schmitz-Rohmer D., Bonnel D., Legouffe R., Barré F., Bekkenk M.W., Haas E.R.M. de, Quint K.D., Rolli M., Streefkerk H.J., Burggraaf J., Vermeer M.H. & Rissmann R. (2022), Topical bimiralisib shows meaningful cutaneous drug levels in healthy volunteers and mycosis fungoides patients but no clinical activity in a first-in-human, randomized controlled trial, Cancers 14(6): 1510.
- Hassing G.J., Esdonk M.J. van, Westen G.J.P. van, Cohen A.F., Burggraaf J. & Gal P. (2022), Dose escalations in phase I studies: feasibility of interpreting blinded pharmacodynamic data, British Journal of Clinical Pharmacology 88(12): 5412-5419.
- Veld A.E. in 't, Jansen M.A.A., Huisman B.W., Schoonakker M., Kam M.L. de, Moes D.J.A.R., Poelgeest M.I.E. van, Burggraaf J. & Moerland M. (2022), Monitoring of ex vivo cyclosporin a activity in healthy volunteers using t cell function assays in relation to whole blood and cellular pharmacokinetics, Pharmaceutics 14(9): 1958.
- Ligt R. de, Westerhout J., Grossouw D., Buters T.P., Rissmann R., Burggraaf J., Windhorst A.D., Tozer S., Pappa G., Wall B., Bury D., Mason D.R. & Vaes W.H.J. (2022), Assessment of dermal absorption of aluminium from a representative antiperspirant formulation using a (Al-26)Al microtracer approach: a follow-up study in humans, Toxicology Research 11(3): 511-519.
- Wall H.E.C. van der Doll R.J., Westen G.J.P. van, Niemeyer-van der Kolk T., Feiss G., Pinckaers H., Doorn M.B.A. van, Nijsten T., Sanders M.G.H., Cohen A.F., Burggraaf J., Rissmann R. & Pardo L.M. (2022), Discriminative machine learning analysis for skin microbiome: observing biomarkers in patients with seborrheic dermatitis, Journal of Artificial Intelligence for Medical Sciences 3(1-2): 1-7.
- Jacobse J., Voorde W. ten, Tandon A., Romeijn S.G., Grievink H.W., Maaden K. van der, Esdonk M.J. van, Moes D.J.A.R., Loeff F., Bloem K., Vries A. de, Rispens T., Wolbink G., Kam M. de, Ziagkos D., Moerland M., Jiskoot W., Bouwstra J., Burggraaf J., Schrier L., Rissmann R. & Cate R. ten (2021), Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial, British Journal of Clinical Pharmacology 87(8): 3162-3176.
- Wall H.E.C. van der, Doll R.J., Westen G.J.P. van, Koopmans I., Zuiker R.G., Burggraaf J. & Cohen A.F. (2021), Using machine learning techniques to characterize sleep-deprived driving behavior, Traffic Injury Prevention 22(5): 366-371.
- Huisman B.W., Cankat M., Bosse T., Vahrmeijer A.L., Rissmann R., Burggraaf J., Sier C.F.M. & Poelgeest M.I.E. van (2021), Integrin αvβ6 as a target for tumor-specific imaging of vulvar squamous cell carcinoma and adjacent premalignant lesions, Cancers 13(23): 6006.
- Goulooze S.C., Kruithof A.C., Alikunju S., Gautam A., Burggraaf J., Kamerling I.M.C. & Stevens J. (2020), The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers, British Journal of Clinical Pharmacology 86(10): 2095-2101.
- Fienieg B., Hassing G.J., Wall H.E.C. van der, Westen G.J.P. van, Kemme M.J.B., Adiyaman A., Elvan A., Burggraaf J. & Gal P. (2020), The association between body temperature and electrocardiographic parameters in normothermic healthy volunteers, Pace Pacing and Clinical Electrophysiology 44(1): 44-53.
- Munckhof E.H.A. van den, Niemeyer-Van der Kolk T., Wall H.E.C. van der, Alewijk D.C.J.G. van, Doorn M.B.A. van, Burggraaf J., Buters T.P., Becker M.J., Feiss G.L., Quint W.G.V., Doorn L.J. van, Knetsch C.W. & Rissmann R. (2020), Inter- and intra-patient variability over time of lesional skin microbiota in adult patients with atopic dermatitis, Acta Dermato-Venereologica 100(1): adv00018.
- Rijsbergen M., Niemeyer-van der Kolk T., Rijneveld R., Pinckaers J.H.F.M., Meshcheriakov I., Bavinck J.N.B., Doorn M.B.A. van, Hogendoorn G., Feiss G., Cohen A.F., Burggraaf J., Poelgeest M.I.E. van & Rissmann R. (2020), Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology, Journal of the European Academy of Dermatology and Venereology 34(3): 633-639.
- Rijsbergen M., Rijneveld R., Todd M., Pagan L., Feiss G., Koning M.N.C. de, Alewijk D.C.J.G. van, Klaassen E.S., Burggraaf J., Rissmann R. & Poelgeest M.I.E. van (2020), No effect of topical digoxin and furosemide gel for patients with external anogenital warts, Journal of the European Academy of Dermatology and Venereology 34(1): E45-E46.
- Niemeyer-van der Kolk T., Assil S., Buters T.P., Rijsbergen M., Klaassen E.S., Feiss G., Florencia E., Prens E.P., Burggraaf J., Doorn M.B.A. van, Rissmann R. & Moerland M. (2020), Omiganan enhances imiquimod-induced inflammatory responses in skin of healthy volunteers, Clinical and Translational Science 13(3): 573-579.
- Huisman B.W., Burggraaf J., Vahrmeijer A.L., Schoones J.W., Rissmann R., Sier C.F.M. & Poelgeest M.I.E. van (2020), Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: a systematic review of candidate biomarkers, Gynecologic Oncology 156(3): 734-743.
- Niemeyer-van der Kolk T., Wall H. van der, Hogendoorn G.K., Rijneveld R., Luijten S., Alewijk D.C.J.G. van, Munckhof E.H.A. van den, Kam M.L. de, Feiss G.L., Prens E.P., Burggraaf J., Rissmann R. & Doorn M.B.A. van (2020), Pharmacodynamic effects of topical Omiganan in patients with mild to moderate atopic dermatitis in a randomized, placebo-controlled, phase II trial, Clinical and Translational Science 13(5): 994-1003.
- Rijsbergen M., Rijneveld R., Todd M., Feiss G.L., Kouwenhoven S.T.P., Quint K.D., Alewijk D.C.J.G. van, Koning M.N.C. de, Klaassen E.S., Burggraaf J., Rissmann R. & Poelgeest M.I.E. van (2020), Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions, British Journal of Clinical Pharmacology 86(11): 2133-2143.
- Kolk T.N. van der, Buters T.P., Krouwels L., Boltjes J., Kam M.L. de, Wall H. van der, Alewijk D.C.J.G. van, Munckhof E.H.A. van den, Becker M.J., Feiss G., Florencia E.F., Prens E.P., Moerland M., Burggraaf J., Rissmann R. & Doorn M.B.A. van (2020), Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial, Journal of The American Academy of Dermatology 86(4): 854-862.
- Wall H.E.C. van der, Doll R.J., Westen G.J.P. van der, Koopmans I., Zuiker R.G., Burggraaf J. & Cohen A.F. (2020), The use of machine learning improves the assessment of drug-induced driving behaviour, Accident Analysis & Prevention 148: 105822.
- Wall H.E.C. van der, Gal P., Kemme M.J.B., Westen G.J.P. van & Burggraaf J. (2019), Number of ECG Replicates Influences the Estimated QT Prolonging Effect of a Drug, Journal of Cardiovascular Pharmacology 73(4): 257-264.
- Hassing G.J., Wall H.E.C. van der, Westen G.J.P. van, Kemme M.J.B., Adiyaman A., Elvan A., Burggraaf J. & Gal P. (2019), Blood pressure-related electrocardiographic findings in healthy young individuals, Blood Pressure 29(22): 113-122.
- Rijsbergen M., Niemeyer-van der Kolk T., Hogendoorn G., Kouwenhoven S., Lemoine C., Klaassen E.S., Koning M. de, Beck S., Bavinck J.N.B., Feiss G., Burggraaf J. & Rissmann R. (2019), A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts, British Journal of Dermatology 180(5): 1058-1068.
- Rijsbergen M., Pagan L., Niemeyer-van der Kolk T., Rijneveld R., Hogendoorn G., Lemoine C., Miranda Y.M., Feiss G., Bavink J.N.B., Burggraaf J., Poelgeest M.I.E. van & Rissmann R. (2019), Stereophotogrammetric three-dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus-induced skin lesions, Journal of the European Academy of Dermatology and Venereology 33(8): 1506-1512.
- Jacobse J., Voorde W. ten, Rissmann R., Burggraaf J., Cate R. ten & Schrier L. (2019), The effect of repeated methotrexate injections on the quality of life of children with rheumatic diseases, European Journal of Pediatrics 178(1): 17-20.
- Ruiter R., Burggraaf J. & Rissmann R. (2019), Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database, British Journal of Clinical Pharmacology 85(4): 838-844.
- Kolk T. van der, Assil S., Rijneveld R., Klaassen E.S., Feiss G., Florencia E., Prens E.P., Burggraaf J., Moerland M., Rissmann R. & Doorn M.B.A. van (2018), Comprehensive, multimodal characterization of an imiquimod-induced human skin inflammation model for drug development, Clinical and Translational Science 11(6): 607-615.
- Hogendoorn G.K., Bruggink S.C., Hermans K.E., Kouwenhoven S.T.P., Quint K.D., Wolterbeek R., Eekhof J.A.H., Koning M.N.C. de, Rissmann R., Burggraaf J. & Bavinck J.N.B. (2018), Developing and validating the Cutaneous WARTS (CWARTS) diagnostic tool: a novel clinical assessment and classification system for cutaneous warts, British Journal of Dermatology 178(2): 527-534.
- Labots G., Jones A., Visser S.J. de, Rissmann R. & Burggraaf J. (2018), Gender differences in clinical registration trials: is there a real problem?, British Journal of Clinical Pharmacology 84(4): 700-707.
- Hogendoorn G.K., Bruggink S.C., Koning M.N.C. de, Eekhof J.A.H., Hermans K.E., Rissmann R., Burggraaf J., Wolterbeek R., Quint K.D., Kouwenhoven S.T.P. & Bavinck J.N.B. (2018), Morphological characteristics and human papillomavirus genotype predict the treatment response in cutaneous warts, British Journal of Dermatology 178(1): 253-260.
- Boon W.M.I. de, Esdonk M.J. van, Stuurman F.E., Biermasz N.R., Pons L., Paty I. & Burggraaf J. (2018), A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced Growth Hormone Secretion In A First-in-human Clinical Trial, Journal of Clinical Endocrinology and Metabolism 104(3): 883-891.
- Esdonk M.J. van, Zutphen E.J.M. van, Roelfsema F., Pereira A.M., Graaf P.H. van der, Biermasz N.R., Stevens J. & Burggraaf J. (2018), How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review, Pituitary 21(3): 310-322.
- Kolk T. van der, Dillingh M.R., Rijneveld R., Klaassen E.S., Koning M.N.C. de, Kouwenhoven S.T.P., Genders R.E., Bavinck J.N.B., Feiss G., Rissmann R. & Burggraaf J. (2017), Topical ionic contra-viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts, Journal of the European Academy of Dermatology and Venereology 31(12): 2088-2090.
- Balak D.M.W., Doorn M.B.A. van, Arbeit R.D., Rijneveld R., Klaassen E., Sullivan T., Brevard J., Thio H.B., Prens E.P., Burggraaf J. & Rissmann R. (2017), IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis, Clinical Immunology 174: 63-72.
- Meer L. van, Moerland M., Gallagher J., Doorn M.B.A. van, Prens E.P., Cohen A.F., Rissmann R. & Burggraaf J. (2017), Injection site reactions after subcutaneous oligonucleotide therapy, British Journal of Clinical Pharmacology 82(2): 340-351.
- Esdonk M.J. van, Burggraaf J., Graaf P.H. van der & Stevens J. (2017), A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds, Journal of Pharmacokinetics and Pharmacodynamics 44(4): 389-400.
- Burggraaf J., Breimer D.D., Graaf P.H. van der. & Lange E.C.M. de (2017), Editorial Special Supplement of the European Journal of Pharmaceutical Sciences on the occasion of the retirement of Professor Meindert Danhof as Professor of Pharmacology at Leiden University, European Journal of Pharmaceutical Sciences 109(Supplement): S1.
- Brill M.J., Rongen A. van, Houwink A.P., Burggraaf J., Ramshorst B. van, Wiezer R.J., Dongen E.P. van & Knibbe C.A. (2014), Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers, Clinical Pharmacokinetics 53(10): 931-941.
- Research Director
- Het beoordelen van onderzoeksvoorstellen Goed geneesmiddelengebruik